Approved Hospital Formulary
Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:
voriconazole
voriconazole
- Formulary
- Restricted --> Suspension restricted to pediatric use in patients who cannot take or tolerate oral tablets.
Last updated: Jun. 28, 2022
- HAZ-MED: Group 3
- Formulary, Not Routinely Stocked: suspension
voriconazole (Vfend) - Criteria for Use
voriconazole (Vfend) IV-to-PO Interchange
Guidelines for IV to PO conversion approved by P&T: Voriconazole 4mg/kg IV q 12: 100mg PO q 12 hours (patient weight <40kg), 200mg PO q 12 hours (patient weight 40-100kg), 300mg PO q 12 hours (patient weight >100kg).
Voriconazole is dosed based on total body weight unless the patient is obese. If patient is obese, voriconazole dose will be based on adjusted body weight.
Adjusted Body weight: IDW + 0.4 (TBW - IBW)
IBW (males) = 45.5kg + (2.3 x inches over 5ft)IBW (females) = 45.5kg + (2.3 x inches over 5ft)
Voriconazole is rounded to the nearest 50 mg increment in adults, round to the nearest whole number for pediatrics.
Voriconazole suspension is not routinely stocked.
Reviewed: September 22, 2009 and 27 Aug 19 (Dose Rounding), February 25, 2020 (voriconazole suspension)